Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HINT1 | P49773 | 5/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064861 | 1.00 | TAS1R3 (0.47) | TAS1R3TAS1R1KDM4EHINT1NT5E | |
| SCHEMBL7066641 | 0.93 | TAS1R3 (0.46) | TAS1R3TAS1R1KDM4EHINT1NT5E | |
| SCHEMBL7066673 | 0.93 | TAS1R3 (0.46) | TAS1R3TAS1R1KDM4EHINT1NT5E | |
| SCHEMBL7066647 | 0.91 | TAS1R3 (0.45) | TAS1R3TAS1R1KDM4EHINT1NT5E | |
| SCHEMBL7066395 | 0.89 | TAS1R3 (0.43) | TAS1R3TAS1R1KDM4EHINT1NT5E | |
| SCHEMBL7063503 | 0.87 | HINT1 (0.53) | TAS1R3TAS1R1HINT1NT5ETAAR1 | |
| SCHEMBL7063499 | 0.87 | HINT1 (0.53) | TAS1R3TAS1R1HINT1NT5ETAAR1 | |
| SCHEMBL5507027 | 0.83 | KDM4E (0.41) | TAS1R3TAS1R1KDM4EHINT1NT5E | |
| SCHEMBL24512507 | 0.82 | TAS1R3 (0.53) | TAS1R3TAS1R1KDM4EHINT1NT5E | |
| SCHEMBL29870610 | 0.82 | TAS1R3 (0.53) | TAS1R3TAS1R1KDM4EHINT1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624294-B2 | Dissolving nucleoside in solvent to form a solution; cooling; treating with base; warming; reacting with ester to effect alkylation of 2' position of a 2',3'-dihydroxy sugar moiety of a nucleoside | ISIS PHARMACEUTICALS, INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | IONIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-6403779-B1 | DISSOLVING NUCLEOSIDE IN APROTIC SOLVENT, COOLING, TREATING WITH BASE, WARMING MIXTURE, COOLING, REACTING WITH REACTIVE ESTER TO EFFECT ALKYLATION | ISIS PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | NSUN2, NT5C3B, RNGTT | TAS1R3 4469/4885TAS1R1 4761/4885KDM4E 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.